Skip to main content

Table 4 Delta changes in the explorative measurements from baseline to follow up time point

From: A randomized controlled trial on a multicomponent intervention for overweight school-aged children – Copenhagen, Denmark

 

n

Control ∆adj

n

Intervention ∆adj

n

Intervention effect ∆adj

P value

Glycemic control

       

 HbA1c (mmol/mol)

12

-0.3 (-0.8; 0.1)

14

-0.5 (-0.9; -0.1)

26

-0.2 (-0.8; 0.5)

0.6

Oral glucose tolerance test

       

  Fasting glucose (mmol/L)

14

0.1 (-0.1;0.3)

14

0.1 (-0.1; 0.2)

28

0.0 (-0.3; 0.3)

0.4

  Fasting insulin (mmol/L)

13

-4.7 (-17.6; 8.2)

12

-13.4 (-26.7; -0.1)

25

-8.7 (-27.4; 10.0)

0.3

  120 min (2 h) glucose (mmol/L)

10

0.6 (-0.1; 1.3)

13

0.1 (-0.5; 0.7)

23

-0.5 (-1.4; 0.4)

0.3

  Matsuda Index

9

-3.4 (-10.2; 3.5)

12

7.4 (1.9; 13.0)

21

10.8 (1.4; 20.2)

P <0.03

  HOMA-IR

13

0.1 (-0.5; 0.3)

12

-0.4 (-0.8; 0.1)

25

-0.3 (-0.9; 0.3)

0.3

 Mean 48 h BG (mmol/L) by CGMS

7

0.1 (-0.6; 0.9)

9

-0.3 (-1.0; 0.4)

16

-0.4 (-1.5; 0.7)

0.4

Biochemistry

       

 Alanintransaminase (U/l)

12

-7.9 (-12.6; -3.3)

14

-9.1 (-13.3; -4.8)

26

-1.1 (-7.4; 5.2)

0.7

 Aspartattransaminase (U/l)

12

-2.0 (-5.1; 1.1)

14

-2.9 (-5.8; 0.0)

26

-0.9 (-5.1; 3.3)

0.7

 Thyrotropin (x10-3int.enh./l)

14

0.1 (-0.4; 0.6)

14

0.3 (-0.1; 0.8)

28

0.2 (-0.5; 0.9)

0.5

 Triiodthyronin (nmol/l)

14

-0.2 (-0.3; 0.0)

14

-0.2 (-0.4; -0.1)

28

-0.1 (-0.3; 0.1)

0.5

 Thyroxin (nmol/l)

14

0.8 (-3.9; 5.5)

14

-0.6 (-5.3; 4.1)

28

-1.4 (-8.0; 5.3)

0.7

 Total cholesterol (mmol/L)

14

-0.3 (-0.5; 0.0)

14

-0.5 (-0.8; -0.3)

28

-0.3 (-0.6; 0.0)

0.07

 LDL (mmol/L)

14

-0.1 (-0.3; 0.1)

14

-0.4 (-0.6; -0.2)

28

-0.3 (-0.6; 0.0)

0.06

 HDL (mmol/L)

14

0.1 (0.0; 0.1)

14

0.0 (-0.1; 0.1)

28

-0.1 (-0.2; 0.1)

0.4

 Triglycerides (mmol/L)

14

-0.1 (-0.2; 0.0)

14

-0.3 (-0.4; -0.1)

28

-0.2 (-0.3; 0.0)

0.1

 Estradiol (pmol/L)

13

-11.8 (-22.4; -1.2)

13

-14.8 (-25.5; -4.1)

26

-3.0 (-18.6; 12.5)

0.7

 Testosterone (nmol/L)

12

0.0 (0.0; 0.1)

13

0.0 (0.0; 0.1)

25

0.00 (-0.1; 0.1)

1

 Sex hormone-binding globulin (nmol/L)

13

4.2 (-2.4; 10.8)

13

17.0 (10.5; 23.5)

26

12.9 (3.5; 22.3)

P <0.01

 Follicle-stimulating hormone (IU/L)

13

0.1 (-0.2; 0.3)

13

0.0 (-0.3; 0.2)

26

-0.1 (-0.4; 0.3)

0.7

 Luteinizing hormone (IU/L)

13

0.0 (-0.1; 0.3)

13

0.0 (-0.2; 0.2)

26

-0.1 (-0.3; 0.2)

0.5

 IGFBP-3 (ng/mL)

13

-73.2 (-233.5; 87.0)

13

-124.5 (-291.0; 42.0)

26

-51.3 (-293.0; 190.4)

0.7

 Insulin-like growth factor 1 (ng/mL)

13

49.8 (15.1; 84.5)

13

4.4 (-30.2; 39.1)

26

-45.4 (-94.5; 3.8)

0.07

 Adiponectin (ng/mL)

12

-1,693 (-3,143; -242)

13

595 (-801; 1,990)

25

2,287 (254; 4,320)

P <0.05

 Leptin (pg/mL)

11

-7,803 (-15,402; -205)

14

-14,374 (-21,069; -7,679)

25

-6,570 (-16,944; 3,803)

0.2

 Resistin (ng/mL)

12

-0.4 (-0.9; 0.1)

14

-0.6 (-1.0; -0.1)

26

-0.2 (-0.8; 0.5)

0.6

 Visfatin (ng/mL)

10

0.0 (-0.3; 0.2)

11

0.2 (-0.1; 0.4)

21

0.2 (-0.2; 0.5)

0.3

  1. P values are representing the intervention effects (the difference in change between the groups) adjusted for the respective baseline values (95% confidence intervals).
  2. P values assessed by ANCOVA.
  3. Mean 48 h BG (mmol/L) by CGMS, mean blood glucose measured in 48 h by continuous glucose monitoring system.
  4. HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IGFBP-3, Insulin-like growth factor-binding protein 3.